OptiNose, Inc. short interest in 2022
In 2022, OptiNose, Inc.'s disclosed short interest ran from 2.70% of shares outstanding on 14 Jan 2022 to 3.11% on 30 Dec 2022, a change of +0.41 percentage points. The year's high was 3.31% on 15 Dec 2022 and its low 2.21% on 28 Feb 2022, averaging 2.74% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 29.92 days on 31 Oct 2022. Full history: OptiNose, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024
2022 in figures
- Start of year
- 2.70% (14 Jan 2022)
- End of year
- 3.11% (30 Dec 2022)
- Change
- +0.41 pp
- High
- 3.31% (15 Dec 2022)
- Low
- 2.21% (28 Feb 2022)
- Average
- 2.74%
- Highest days to cover
- 29.92 (31 Oct 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 2.70% | 6.73 | |
| 31 Jan 2022 | 2.52% | 7.24 | |
| 15 Feb 2022 | 2.57% | 5.94 | |
| 28 Feb 2022 | 2.21% | 6.08 | |
| 15 Mar 2022 | 2.65% | 4.79 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 3.09% | 4.87 | |
| 14 Apr 2022 | 2.99% | 15.84 | |
| 29 Apr 2022 | 2.99% | 23.79 | |
| 13 May 2022 | 2.43% | 10.43 | 10-Q filed, results (8-K) |
| 31 May 2022 | 2.40% | 26.93 | |
| 15 Jun 2022 | 2.55% | 3.82 | |
| 30 Jun 2022 | 2.61% | 7.43 | |
| 15 Jul 2022 | 2.53% | 9.75 | |
| 29 Jul 2022 | 2.53% | 25.58 | |
| 15 Aug 2022 | 2.47% | 10.46 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 2.50% | 16.25 | |
| 15 Sep 2022 | 2.48% | 20.41 | |
| 30 Sep 2022 | 3.07% | 15.51 | |
| 14 Oct 2022 | 3.12% | 29.01 | |
| 31 Oct 2022 | 3.18% | 29.92 | |
| 15 Nov 2022 | 2.99% | 18.76 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 2.85% | 6.79 | |
| 15 Dec 2022 | 3.31% | 6.19 | |
| 30 Dec 2022 | 3.11% | 19.14 |
See also: OptiNose, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.